Less Ads, More Data, More Tools Register for FREE

Pin to quick pickseEnergy Group Regulatory News (EAAS)

Share Price Information for eEnergy Group (EAAS)

Share Price is delayed by 15 minutes
Get Live Data
5.05    0.00 (0.00%)
Bid:
4.80
Ask:
5.30
Spread: 0.50 (10.417%)
Market Cap: £19.55m
EAAS Live PriceLast checked at - London Stock Exchange

Intraday eEnergy Group Share Chart

Patent Granted

27 Sep 2012 07:00

RNS Number : 2505N
Alexander Mining PLC
27 September 2012
 



27 September 2012

Alexander Mining plc

('Alexander' or the 'Company')

First 'MoReLeach' Patent Granted for a Method Oxidative Leaching of Molybdenum - Rhenium Sulfide Ores and/or Concentrates in Australia

Alexander is pleased to report that it has received notification that its MetaLeach Limited ("MetaLeach") subsidiary has been granted a patent for a Method Oxidative Leaching of Molybdenum - Rhenium Sulfide Ores and/or Concentrates in Australia, patent number 2011229125. The patent has a standard term of twenty years from 3 March 2011 (being the date of original filing), and is directed to the MoReLeach technology, a sister technology to the Company's HyperLeach® technology (patents pending).

The patent describes a method for leaching molybdenum and/or rhenium from a sulfide ore and/or concentrate containing such, the method comprising the steps of:

·; Exposing the ore and/or concentrate to an aqueous solution of chlorine-based oxidising species in which the sum of the concentrations of hypochlorite and hypochlorous acid is at least 10mol% of the chlorine-based oxidising species;

·; Allowing and/or facilitating the oxidation of the molybdenum and/or rhenium by the hypochlorite and/or hypochlorous acid, thereby decreasing the pH such that the predominant chlorine-based oxidising species becomes chlorine;

·; Allowing and/or facilitating the oxidation of the molybdenum and/or rhenium by the chlorine thereby producing a pregnant leach solution; and

·; Passing the pregnant leach solution to a means for metal recovery.

The MoReLeach Process

The MoReLeach process, a sister technology to the Company's HyperLeach® technology, is used on molybdenum bearing ores, concentrates and flotation tailings. The HyperLeach® process is a process for the extraction of base metals, especially copper, zinc, nickel and cobalt from sulphidic ores and concentrates.

The technology consists of three major stages i.e. leaching, separation/concentration and recovery. The leaching can occur either in heap or tank and involves contacting the ore/concentrate with a suitable solution of reagent at an appropriate concentration. The separation/concentration and recovery of the metals uses the same ion exchange process as that used in current roasting - acid leach plants to produce the industry standard products, ammonium molybdate and ammonium perrhenate, which can be sold directly to secondary processors. The reagent used can be readily recycled at low cost using conventional technologies.

Using MoReLeach both oxide and sulphide based molybdenum ores can be effectively treated. The reagent used is highly selective for molybdenite and can be used to remove molybdenum from copper flotation concentrates whilst minimising copper loss. This allows realisation of the value of the molybdenum, increases the copper grade and reduces penalties at the copper smelter. The rhenium which is present in all molybdenite deposits will behave in the same way as molybdenum and can be recovered at low additional cost.

Martin Rosser, Chief Executive Officer, said: "The granting of our first MoReLeach patent for the potential application of the technology described in the patent for molybdenum and rhenium ores is a significant addition to the range of metals covered by the Company's leaching technology."

Forward Looking Statements

This news release may contain forward looking statements, being statements which are not historical facts, including, without limitation, statements regarding potential mineralization, exploration results, resource or reserve estimates, anticipated production or results, sales, revenues, costs, "best-efforts" financings or discussions of future plans and objectives. There can be no assurance that such statements will prove accurate. Such statements are necessarily based upon a number of estimates and assumptions that are subject to numerous risks and uncertainties that could cause actual results and future events to differ materially from those anticipated or projected. Important factors that could cause actual results to differ materially from the Company's expectations are in Company documents filed from time to time with the TSX Venture Exchange and provincial securities regulators, most of which are available at www.sedar.com. The Company disclaims any intention or obligation to revise or update such statements unless required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

ENDS

For further information please contact: 

Martin Rosser Matt Sutcliffe

Chief Executive Officer Executive Chairman

Mobile: + 44 (0) 7770 865 341 Mobile: +44 (0) 7887 930 758

 

Alexander Mining plc

1st Floor

35 Piccadilly

London

W1J 0DW

Tel: +44 (0) 20 7292 1300

Fax: +44 (0) 20 7292 1313

Email: mail@alexandermining.com

Website: www.alexandermining.com

 

Nominated Advisor and Broker

RFC Ambrian Limited

Samantha Harrison / Jen Boorer

+44 (0) 20 3440 6800

 

Public/Media Relations

Britton Financial PR

Tim Blackstone

+44 (0) 20 7242 9786

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRLLFLEAVIRFIF
Date   Source Headline
1st Jun 20267:00 amRNSPublication of AR, Notice of AGM and Board Update
18th May 20267:00 amRNSDirectorate change
13th May 20267:00 amRNSBoard changes
30th Apr 20267:00 amRNSFinal Results for the Year Ended 31 December 2025
16th Apr 20267:00 amRNSQ1 Trading Update, Revenue Recognition & Outlook
4th Mar 20267:00 amRNS-RContract wins
23rd Feb 20267:00 amRNSLoan Agreement
23rd Jan 20267:00 amRNSTrading Update
22nd Jan 20267:00 amRNSLaunch of new funding solution and first contract
19th Jan 20267:00 amRNSAppointment of Non-Executive Director
15th Dec 20257:00 amRNSFY Trading Update
27th Nov 20257:00 amRNSDirectorate change
17th Nov 20253:20 pmRNSAward of Options
12th Nov 20254:38 pmRNSSolar Agreement, Loan Agreement, Grant of Warrants
29th Oct 202511:39 amRNSHolding(s) in Company
27th Oct 20257:00 amRNS-RLargest EV Charging Project to Date with NHS
23rd Oct 20252:10 pmRNSHolding(s) in Company
20th Oct 20251:28 pmRNSHolding(s) in Company
1st Sep 20257:00 amRNSPreferred supplier for major solar contract
22nd Aug 20253:04 pmRNSHolding(s) in Company
21st Aug 20253:09 pmRNSHolding(s) in Company
19th Aug 202510:50 amRNSHolding(s) in Company
7th Aug 202512:13 pmRNSHolding(s) in Company
31st Jul 20255:17 pmRNSResult of AGM
22nd Jul 20257:00 amRNSUnaudited HY Results - Six Months Ended 30.06.25
3rd Jul 202510:46 amRNSNotice of AGM
30th Jun 20257:00 amRNSNotice of Results
13th Jun 20259:30 amRNSNotice of FY Results and Investor Presentation
3rd Jun 20259:25 amRNSHolding(s) in Company
20th May 202511:10 amRNSHolding(s) in Company
16th May 20257:00 amRNS£100m Partnership with Redaptive
7th Apr 20257:00 amRNS-RFramework win
26th Mar 20257:00 amRNS-RLaunch of SolarLife
24th Mar 20257:00 amRNS-RContracts wins and appointment to a Framework
11th Mar 20257:00 amRNS-RContract Wins
12th Feb 202511:17 amRNSHolding(s) in Company
3rd Feb 20257:00 amRNS-RInvestor Meet Company Presentation
30th Jan 20257:00 amRNSTrading update
19th Dec 20241:45 pmRNSAward of Options and PDMR Transactions
28th Nov 20247:00 amRNS-RLED Conversion Contract in Further Education
15th Oct 202410:45 amRNSHolding(s) in Company
1st Oct 20247:00 amRNSDirector appointment - additional information
30th Sep 20247:00 amRNSResults for the six months ended 30 June 2024
6th Sep 20247:00 amRNSHolding(s) in Company
8th Aug 20247:00 amRNSInvestor Presentations
26th Jul 20247:00 amRNSH1 24 Trading Update
28th Jun 20243:03 pmRNSResult of AGM
13th Jun 20247:00 amRNSNotice of General Meeting
30th Apr 20247:01 amRNSFinal Results for the 18 months ended 31 Dec 2023
22nd Apr 20247:00 amRNSMajor Contract Win with Spire Healthcare

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.